[2 cases of acute cholestasis caused by ticlopidine].
We report the case of two patients suffered from cholestatic jaundice occurred 3-4 weeks after starting ticlopidine therapy. In both cases the diagnosis was made by ruling out any other known cause of acute hepatitis or cholestasis. One patient underwent liver biopsy, which showed a typical intralobular cholestatic pattern and a slight lymphocytic infiltration of the portal tracts. The other patient, a 29 year-old woman, was taking ticlopidine as the sole drug, further to an ischemic stroke occurred while she was taking oral contraceptives; she presented a diffuse itchy dermatitis, fever and slight eosinophilia besides cholestasis. In both patients ticlopidine was discontinued and liver tests returned to normal values within 4-8 weeks; no rechallenge was attempted and ticlopidine was replaced with another antiplatelet drug. To the best of our knowledge 19 cases of ticlopidine-related cholestatic disease have been described so far in the literature. Its pathogenesis is still unknown, although some clinical findings and experimental results from patients with acute enteropathy or agranulocytosis induced by ticlopidine suggest that the drug may act through a toxic mechanism, perhaps mediated by prostaglandins.
Guzzini
F
F
Servizio di Accettazione e Pronto Soccorso, USSL, Ospedale, Saronno (Varese).
Banfi
L
L
Gomitoni
A
A
Marchegiani
C
C
Novati
P
P
Mesina
M
M
Frigerio
B
B
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001706:Biopsy; D002779:Cholestasis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine